<code id='95CDD8DA77'></code><style id='95CDD8DA77'></style>
    • <acronym id='95CDD8DA77'></acronym>
      <center id='95CDD8DA77'><center id='95CDD8DA77'><tfoot id='95CDD8DA77'></tfoot></center><abbr id='95CDD8DA77'><dir id='95CDD8DA77'><tfoot id='95CDD8DA77'></tfoot><noframes id='95CDD8DA77'>

    • <optgroup id='95CDD8DA77'><strike id='95CDD8DA77'><sup id='95CDD8DA77'></sup></strike><code id='95CDD8DA77'></code></optgroup>
        1. <b id='95CDD8DA77'><label id='95CDD8DA77'><select id='95CDD8DA77'><dt id='95CDD8DA77'><span id='95CDD8DA77'></span></dt></select></label></b><u id='95CDD8DA77'></u>
          <i id='95CDD8DA77'><strike id='95CDD8DA77'><tt id='95CDD8DA77'><pre id='95CDD8DA77'></pre></tt></strike></i>

          
          WSS
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          Wikipedia